secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002861
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera preliminary Q4 rev ~$660M (+39% YoY), FY rev ~$2.3B (+35%), above outlook
--------------------------------------------------------------------------------

- Q4 total revenue ~$660M (+39% YoY); FY 2025 ~$2.3B (+35%), ~$40M above top end of prior outlook.
- Oncology tests Q4: 233,300 total (225,300 clinical MRD), up 55% YoY; record sequential growth of ~22,800 MRD tests.
- Total tests processed Q4: 923,600 (+17% YoY); FY: 3,525,500 (+15%).
- Cash inflows Q4 ~$30M; FY >$100M, driven by operational improvements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465926002861/0001104659-26-002861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465926002861/tm262952d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer